Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer disease

Neurobiol Aging. 2012 Feb;33(2):416-417.e3. doi: 10.1016/j.neurobiolaging.2010.03.003. Epub 2010 Apr 9.

Abstract

The Alzheimer amyloid protein precursor (APP) is subject to proteolysis by ADAM10 and ADAM17, precluding the formation of Aβ. Recently, coding variations in ADAM10 resulting in altered function have been reported in familial Alzheimer disease (AD). The authors carried out a large-scale (n = 576: Controls, 271; AD, 305) resequencing study of ADAM10 in sporadic AD. The results do not support a significant role for ADAM10 mutations in AD. The results also make it clear that the careful examination of ancestry required in any case-control comparison is especially true with rare variations, where even a very small number of variations might form the basis of scientific conclusions.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM Proteins / genetics*
  • ADAM10 Protein
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / epidemiology*
  • Alzheimer Disease / genetics*
  • Amyloid Precursor Protein Secretases / genetics*
  • Genetic Predisposition to Disease / epidemiology*
  • Genetic Predisposition to Disease / genetics*
  • Humans
  • Membrane Proteins / genetics*
  • Middle Aged
  • Mutation / genetics*
  • Polymorphism, Single Nucleotide / genetics*
  • Prevalence
  • Risk Assessment
  • Risk Factors
  • United States / epidemiology

Substances

  • Membrane Proteins
  • Amyloid Precursor Protein Secretases
  • ADAM Proteins
  • ADAM10 Protein
  • ADAM10 protein, human